● Recruiting

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer · Sponsor: Liu Huang

PhasePhase 1/Phase 2

Planned participants42

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Glumetinib combined withFruquintinib in the treatment of MET amplification or protein overexpression in third-line unresectable metastatic colorectal cancer: evaluation of efficacy and safety

This description comes directly from the study's public registry record.

Talk to the study team

Xianglin Yuan, PhD,MD · 13667241722 · Xlyuan1020@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Huazhong University of Science and Technology

Wuhan, Hubei, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06980532